Ocular Safety and Usability Study for FYB203 PFS

NCT06708637 | Completed Phase 4 FDA Drug

• 1 other identifier: FYB203-04-01
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 4

Brief Summary

The objective of the study is to assess the ocular safety of the FYB203 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.

Conditions

Age-Related Macular Degeneration; Branch Retinal Vein Occlusion with Macular Edema; Central Retinal Vein Occlusion with Macular Edema; Diabetic Macular Edema; Diabetic Retinopathy

Outcome Measures

Primary Outcomes (1)

• Incidence and occurrence of ocular and non-ocular Adverse Events (AEs) and Serious Adverse Events (SAEs) occurring after IVT injection

  To assess the ocular safety of the FYB203 PFS in terms of preparation and administration by Retina Specialists.

  2 days

Study Arms (1)

FYB203 2 mg (0.05 mL of 40 mg/mL)

EXPERIMENTAL

FYB203 provided in a pre-filled syringe (PFS), containing 2 mg of 40 mg/mL aflibercept in 0.05 mL for intravitreal (IVT) administration

Drug: FYB203 2 mg (0.05 mL of 40 mg/mL)

Interventions

FYB203 2 mg (0.05 mL of 40 mg/mL) DRUG

IVT administration of FYB203 in a PFS

Also known as: aflibercept-mrbb

FYB203 2 mg (0.05 mL of 40 mg/mL)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Study eye deemed to be indicated for aflibercept IVT injection therapy at the discretion of the Investigator.
• Written and signed informed consent form (ICF) obtained before any study-related procedures.
• Had a confirmed diagnosis in one or both eyes of neovascular (wet) AMD or macular edema following RVO or DME or DR.
• Qualified for treatment with aflibercept according to the United States Prescribing Information.
• Aged ≥18 years at the time of signing ICF.
• If a subject was already on an aflibercept regimen, timing of study participation was correlated with the regimen.
• Male study subject (if his female spouse/partner was of childbearing potential) must have confirmed that he was using two acceptable methods for contraception (one of which must be a barrier method) starting at signing ICF and throughout the clinical study period and for 3 months after IP administration. Male study subject must have agreed to inform his partner of participation in the study and the need to avoid pregnancy. Surgically sterilized and non sexually active male subjects did not require any additional use of contraception.
• Male study subject agreed not to donate sperm starting from screening and throughout the clinical study period and for 3 months after IP administration.
• Female study subject was categorized by at least one of the following:
• Not a woman of childbearing potential as described in Appendix 3 of the study protocol prior to signing ICF, or
• Surgically sterile or had undergone a hysterectomy as categorized in Appendix 3 of the study protocol at least 1 month prior to signing ICF, or
• Was using a highly effective contraception. All females of childbearing potential were required to use highly effective contraception (as described in Appendix 3 of the study protocol) starting at signing ICF and throughout the clinical study period and for 3 months after IP administration.
• Female study subject must not be lactating and must not be breastfeeding at screening until 3 months after IP administration.
• Female study subject must not donate ova starting at signing ICF and throughout the clinical study period and for 3 months after IP administration.

You may not qualify if:

• Had received IVT injection in the study eye within 3 months prior to Day 1 with any anti vascular endothelial growth factor therapy other than aflibercept products (ege.g., Eylea).
• Intraocular corticosteroid administration in the study eye within 30 days prior to Day 1.
• Had fever or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non cutaneous) infection within 1 week prior to Day 1.
• History or evidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in the last month prior to signing ICF or had been in confirmed contact with SARS-CoV-2 positive subjects in the last 2 weeks before dosing.

Sponsors & Collaborators

• Formycon AG: lead

Study Sites (4)

Research Site

Campbell, California, 95008, United States

Location

Research Site

Long Beach, California, 90807, United States

Location

Research Site

Redlands, California, 92374, United States

Location

Research Site

Eugene, Oregon, 97401, United States

Location

MeSH Terms

Conditions

Macular Degeneration; Diabetic Retinopathy

Condition Hierarchy (Ancestors)

Retinal Degeneration; Retinal Diseases; Eye Diseases; Diabetic Angiopathies; Vascular Diseases; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 25, 2024
• First Posted: November 27, 2024
• Study Start: September 20, 2024
• Primary Completion: October 8, 2024
• Study Completion: October 8, 2024
• Last Updated: November 27, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (4)